Pre-eclampsia is associated with complement pathway activation in the maternal and fetal circulation, and placental tissue.


Journal

Pregnancy hypertension
ISSN: 2210-7797
Titre abrégé: Pregnancy Hypertens
Pays: Netherlands
ID NLM: 101552483

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 09 09 2022
revised: 21 02 2023
accepted: 11 04 2023
medline: 29 5 2023
pubmed: 24 4 2023
entrez: 23 04 2023
Statut: ppublish

Résumé

Pre-eclampsia (PE) is a leading cause of obstetric morbidity, with no definitive therapy other than delivery. We aimed to compare complement markers in maternal and fetal circulation, and placental tissue, between women with PE and healthy pregnant controls. Maternal and umbilical cord blood was tested for iC3b, C3, C4, properdin, Ba and C5b-9, and placental tissue for C3d, C4d, C9 and C1q, from women with PE (n = 34) and healthy pregnant controls (n = 33). Maternal properdin and Ba tests were repeated in a separate validation cohort (PE n = 35; healthy pregnant controls n = 35). Complement concentrations in maternal and umbilical cord blood, and placental immunohistochemical complement deposition. Women with PE had significantly lower concentrations of properdin (mean: 4828 vs 6877 ng/ml, p < 0.001) and C4 (mean: 0.20 vs 0.31 g/l, p < 0.001), and higher Ba (median: 150 vs 113 ng/ml, p = 0.012), compared to controls. After controlling for gestational age at blood draw, average properdin concentration was 1945 ng/ml lower in PE vs controls (95 % CI: 1487-2402, p < 0.001). Of the cord blood markers assessed, only Ba differed significantly between PE and controls (median: 337 vs 233 ng/ml, p = 0.004). C4d staining of the syncytiotrophoblast membrane was increased in PE vs controls (median immunoreactivity score 3 vs 0, p < 0.001). Maternal properdin and C4 were significantly negatively correlated with placental C4d staining. Our data confirm excessive placental complement deposition associated with significant concurrent changes in maternal and fetal circulating complement biomarkers in PE. Inhibition of complement activation is a potential therapeutic target.

Identifiants

pubmed: 37088032
pii: S2210-7789(23)00018-1
doi: 10.1016/j.preghy.2023.04.001
pii:
doi:

Substances chimiques

Properdin 11016-39-0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-49

Informations de copyright

Crown Copyright © 2023. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hannah Blakey (H)

Renal Medicine Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. Electronic address: hannahblakey@nhs.net.

Ruyue Sun (R)

Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.

Long Xie (L)

Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.

Rebecca Russell (R)

Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.

Nadia Sarween (N)

Renal Medicine Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

James Hodson (J)

Research Development and Innovation, Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Beata Hargitai (B)

Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Tamas Marton (T)

Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Desley A H Neil (D)

Renal Medicine Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Edwin Wong (E)

National Renal Complement Therapeutics Centre, Newcastle, UK.

Neil S Sheerin (NS)

National Renal Complement Therapeutics Centre, Newcastle, UK.

Kate Bramham (K)

Department of Women and Children's Health, King's College London, London, UK.

Claire L Harris (CL)

Translational and Clinical Research Institute, Newcastle University, Newcastle, UK.

Ellen Knox (E)

Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.

Mark Drayson (M)

Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.

Graham Lipkin (G)

Renal Medicine Department, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH